Auro Medics Pharma Llc Sustainability Profile
Auro Medics Pharma LLC, headquartered in the United States, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of high-quality generic medications. Founded in 2006, the company has established a strong presence in key operational regions, including North America and beyond, focusing on delivering affordable healthcare solutions. Auro Medics Pharma is renowned for its extensive portfolio of products, which includes a wide range of oral solid dosage forms and injectables. The company’s commitment to quality and innovation sets it apart, ensuring that its offerings meet rigorous regulatory standards. With a reputation for reliability and excellence, Auro Medics has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Auro Medics Pharma Llc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Auro Medics Pharma Llc's score of 43 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Auro Medics Pharma LLC, headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Aurobindo Pharma Limited, which may influence its climate commitments and emissions reporting. As of now, Auro Medics Pharma has not established any documented reduction targets or climate pledges. The absence of specific emissions data suggests that the company may still be in the early stages of developing its sustainability strategy or reporting framework. The emissions data and performance metrics may be inherited from its parent company, Aurobindo Pharma Limited, which operates under the broader context of industry standards for climate action. However, without explicit figures or targets from Auro Medics Pharma, it is challenging to assess its individual contributions to carbon reduction or climate commitments. In summary, while Auro Medics Pharma LLC is part of a larger corporate family that may have climate initiatives, specific emissions data and reduction targets for the company itself are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 409,572,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 523,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 |
How Carbon Intensive is Auro Medics Pharma Llc's Industry?
How Carbon Intensive is Auro Medics Pharma Llc's Location?
Auro Medics Pharma Llc's Scope 3 Categories Breakdown
Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 23% of total emissions under the GHG Protocol, with "Fuel and Energy Related Activities" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Auro Medics Pharma Llc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Auro Medics Pharma Llc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
